Kary Whitehead, MD
Sleep Medicine · Meridian, MSNPI 1215933924
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,240 of the $1,965 with a category attached, or 63.1%. 12 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 47.1% of the total. Reporting peaked in 2020 at $726 and has fallen 57.2% since, to $311 in 2025.
Across 44 payments — averaging $44.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$925
- Jazz Pharmaceuticals Inc.$513
- Harmony Biosciences LLC$172
- 3b Medical, Inc.$117
- Philips North America LLC$55
- Avadel CNS Pharmaceuticals, LLC$50
- plus $134 from 6 others
What the payments were for
- Travel & lodging$62532%
- Food & beverage$1,24063%
- Education$1005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 4 | $925 |
| Jazz Pharmaceuticals Inc. | 18 | $513 |
| Harmony Biosciences LLC | 9 | $172 |
| 3b Medical, Inc. | 3 | $117 |
| Philips North America LLC | 1 | $55 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Itamar Medical Inc | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few sleep medicine providers in Mississippito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Modafinil | 20 | $4,580 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 24 | $511 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 53 | $300 |
| Gabapentin | 28 | $227 |
| Oxycodone Hcl | 25 | $197 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $106 |
| Clonazepam | 32 | $78 |
| Temazepam | 25 | $49 |
Paid to pharmacies, not to this prescriber.
Other sleep medicine in Meridian
- Brenda HinesFlowood$56K
- Andrea LewisJackson$36K
- Christopher KarcherOcean Springs$26K
- John DouglasGulfport$8K
- Gowdhami MohanClarksdale$5K
- Sanjay RatnakantSouthaven$2K
- John BoswellColumbus$2K
- Mohammad UllahJackson$2K
- Alexandra EdwardsLaurel$1K
- Dani ChoufaniJackson$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.